https://news.medxy.ai/zh/liver-transplant-perfusion-comparison/Medxy AIzh2026-09-12T10:28:42-07:00肝移植中低温氧合灌注与常温机器灌注的真实世界结局比较 https://news.medxy.ai/ja/hypothermic-vs-normothermic-perfusion/Medxy AIja2026-09-12T10:28:23-07:00肝移植における低体温酸素化灌流と常温機械灌流の実臨床成績を比較する https://news.medxy.ai/vi/liver-transplant-blood-flow/Medxy AIvi2026-09-12T10:28:00-07:00So sánh kết cục thực tế của tưới máu ôxy hóa hạ thân nhiệt và tưới máu máy ở nhiệt độ bình thường trong ghép gan https://news.medxy.ai/comparative-real-world-outcomes-of-hypothermic-oxygenated-and-normothermic-machine-perfusion-in-liver-transplantation/Medxy AIen2026-09-12T10:27:41-07:00Comparative Real-World Outcomes of Hypothermic Oxygenated and Normothermic Machine Perfusion in Liver Transplantation https://news.medxy.ai/zh/dexamethasone-levels/Medxy AIzh2026-09-12T10:25:24-07:001 mg 过夜地塞米松抑制试验中血清地塞米松水平的决定因素：临床与药理学启示 https://news.medxy.ai/ja/dexamethasone-levels-3/Medxy AIja2026-09-12T10:25:02-07:001 mg夜間デキサメタゾン抑制試験における血清デキサメタゾン濃度の規定因子：臨床・薬理学的考察 https://news.medxy.ai/vi/dexamethasone-levels-2/Medxy AIvi2026-09-12T10:24:37-07:00Nồng độ dexamethasone huyết thanh trong nghiệm pháp ức chế dexamethasone qua đêm 1 mg: Những yếu tố quyết định và ý nghĩa lâm sàng https://news.medxy.ai/determinants-of-serum-dexamethasone-levels-during-the-1-mg-overnight-dexamethasone-suppression-test-clinical-and-pharmacological-insights/Medxy AIen2026-09-12T10:24:17-07:00Determinants of Serum Dexamethasone Levels During the 1-mg Overnight Dexamethasone Suppression Test: Clinical and Pharmacological Insights https://news.medxy.ai/zh/10khz-spinal-stimulation-2/Medxy AIzh2026-09-12T10:23:27-07:0010 kHz 高频脊髓刺激：推动疼痛性糖尿病周围神经病变的镇痛与感觉恢复 https://news.medxy.ai/ja/10khz-spinal-stimulation/Medxy AIja2026-09-12T10:23:05-07:0010 kHz高周波脊髄刺激で切り拓く疼痛性糖尿病性ニューロパチー治療：疼痛緩和と感覚回復の新展開 https://news.medxy.ai/vi/spinal-cord-stimulation-2/Medxy AIvi2026-09-12T10:22:40-07:00Kích thích tủy sống tần số cao 10 kHz: Bước tiến trong giảm đau và phục hồi cảm giác ở đau do bệnh thần kinh đái tháo đường https://news.medxy.ai/high-frequency-10-khz-spinal-cord-stimulation-advancing-pain-relief-and-sensory-recovery-in-painful-diabetic-neuropathy/Medxy AIen2026-09-12T10:22:20-07:00High-Frequency 10-kHz Spinal Cord Stimulation: Advancing Pain Relief and Sensory Recovery in Painful Diabetic Neuropathy https://news.medxy.ai/zh/tropical-cyclones-heart-disease/Medxy AIzh2026-09-12T10:21:22-07:00热带气旋与急性冠脉综合征：揭示中国大陆的心血管负担 https://news.medxy.ai/ja/tropical-storm-cardiovascular/Medxy AIja2026-09-12T10:21:05-07:00熱帯低気圧と急性冠症候群：中国本土における心血管負担を読み解く https://news.medxy.ai/vi/tropical-vortex-cardiac/Medxy AIvi2026-09-12T10:20:45-07:00Xoáy thuận nhiệt đới và hội chứng vành cấp: Làm rõ gánh nặng tim mạch tại Trung Quốc đại lục https://news.medxy.ai/tropical-cyclones-and-acute-coronary-syndromes-unraveling-the-cardiovascular-burden-in-mainland-china/Medxy AIen2026-09-12T10:20:26-07:00Tropical Cyclones and Acute Coronary Syndromes: Unraveling the Cardiovascular Burden in Mainland China https://news.medxy.ai/zh/gene-perspective-left-heart-failure/Medxy AIzh2026-09-12T10:19:45-07:00基因视角揭示左心发育不全综合征早发心衰风险：NC-DEFINE研究新发现 https://news.medxy.ai/ja/early-left-heart-failure-risk/Medxy AIja2026-09-12T10:19:27-07:00低形成左心症候群の早期心不全リスクをめぐる遺伝学的知見：NC-DEFINE研究の成果 https://news.medxy.ai/vi/left-heart-failure-risk/Medxy AIvi2026-09-12T10:19:06-07:00Phát hiện di truyền mới về nguy cơ suy tim sớm trong hội chứng thiểu sản tim trái: Kết quả từ nghiên cứu NC-DEFINE https://news.medxy.ai/genetic-insights-into-early-heart-failure-risk-in-hypoplastic-left-heart-syndrome-findings-from-the-nc-define-study/Medxy AIen2026-09-12T10:18:45-07:00Genetic Insights into Early Heart Failure Risk in Hypoplastic Left Heart Syndrome: Findings from the NC-DEFINE Study https://news.medxy.ai/zh/dilated-cardiomyopathy-genetics-2/Medxy AIzh2026-09-12T10:17:55-07:00扩张型心肌病遗传学版图再扩展：2024年全面再评估 https://news.medxy.ai/ja/72886-2/Medxy AIja2026-09-12T10:17:38-07:00拡張型心筋症における新たな展望：2024年における包括的な遺伝学的再評価 https://news.medxy.ai/vi/dilated-cardiomyopathy-genetics/Medxy AIvi2026-09-12T10:17:17-07:00Bệnh cơ tim giãn: Đánh giá lại toàn diện di truyền năm 2024 https://news.medxy.ai/expanding-horizons-in-dilated-cardiomyopathy-a-comprehensive-genetic-reassessment-in-2024/Medxy AIen2026-09-12T10:16:59-07:00Expanding Horizons in Dilated Cardiomyopathy: A Comprehensive Genetic Reassessment in 2024 https://news.medxy.ai/zh/s1p-trem2-axis/Medxy AIzh2026-09-12T10:09:31-07:00解密 S1P-TREM2 轴：驱动肝细胞癌免疫抑制性中性粒细胞与肿瘤进展的新型铁死亡抵抗机制 https://news.medxy.ai/ja/s1p-trem2-liver-cancer/Medxy AIja2026-09-12T10:09:08-07:00S1P-TREM2軸の解明：肝細胞癌における免疫抑制性好中球と腫瘍進展を駆動する新規フェロトーシス抵抗機構 https://news.medxy.ai/vi/72865-2/Medxy AIvi2026-09-12T10:08:46-07:00Trục S1P-TREM2 thúc đẩy các bạch cầu trung tính ức chế miễn dịch và sự tiến triển của khối u trong ung thư biểu mô tế bào gan https://news.medxy.ai/unraveling-the-s1p-trem2-axis-a-novel-ferroptosis-resistance-mechanism-driving-immunosuppressive-neutrophils-and-tumour-progression-in-hepatocellular-carcinoma/Medxy AIen2026-09-12T10:08:24-07:00Unraveling the S1P-TREM2 Axis: A Novel Ferroptosis-Resistance Mechanism Driving Immunosuppressive Neutrophils and Tumour Progression in Hepatocellular Carcinoma https://news.medxy.ai/zh/pregnancy-outcomes-leukemia/Medxy AIzh2026-09-12T10:05:40-07:00儿童与青少年急性白血病女性幸存者妊娠结局受何影响：HSCT预处理方案与常规化疗的比较 https://news.medxy.ai/ja/pediatric-leukemia-pregnancy/Medxy AIja2026-09-12T10:05:23-07:00小児・思春期急性白血病女性生存者における前処置レジメンが妊娠転帰へ及ぼす影響：HSCTと従来の化学療法の比較 https://news.medxy.ai/vi/conditioning-protocol-pregnancy/Medxy AIvi2026-09-12T10:05:03-07:00Ảnh hưởng của phác đồ điều kiện hóa đến kết cục thai kỳ ở nữ sống sót sau bệnh bạch cầu cấp tính thời thơ ấu và vị thành niên: HSCT so với hóa trị liệu thông thường https://news.medxy.ai/impact-of-conditioning-regimens-on-pregnancy-outcomes-in-female-survivors-of-childhood-and-adolescent-acute-leukemia-hsct-versus-conventional-chemotherapy/Medxy AIen2026-09-12T10:04:43-07:00Impact of Conditioning Regimens on Pregnancy Outcomes in Female Survivors of Childhood and Adolescent Acute Leukemia: HSCT versus Conventional Chemotherapy https://news.medxy.ai/zh/aml-transplantation-outcomes/Medxy AIzh2026-09-12T10:03:58-07:00AML异基因移植中，诱导疗程数与移植后环磷酰胺结局的关系 https://news.medxy.ai/ja/aml-remission-cycles-impact/Medxy AIja2026-09-12T10:03:38-07:00AMLにおける寛解導入回数は移植成績に影響するか――PTCy併用同種造血幹細胞移植の検討 https://news.medxy.ai/vi/chemo-cycles-aml/Medxy AIvi2026-09-12T10:03:14-07:00Ảnh hưởng của số đợt hóa trị tấn công đến kết cục ghép tế bào gốc dị sinh có cyclophosphamide sau ghép trong AML https://news.medxy.ai/impact-of-induction-course-number-on-outcomes-of-allogeneic-stem-cell-transplant-with-post-transplant-cyclophosphamide-in-aml/Medxy AIen2026-09-12T10:02:55-07:00Impact of Induction Course Number on Outcomes of Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide in AML https://news.medxy.ai/zh/tp53-leukemia-treatment/Medxy AIzh2026-09-12T09:58:40-07:00TP53 突变急性髓系白血病中阿扎胞苷与地西他滨疗效比较：来自 COMMAND 登记研究的启示 https://news.medxy.ai/ja/tp53-aml-treatment-comparison/Medxy AIja2026-09-12T09:58:21-07:00TP53変異AMLにおけるアザシチジンとデシタビンの比較有効性：COMMANDレジストリから見えた知見 https://news.medxy.ai/vi/azacitidine-decitabine-aml-tp53/Medxy AIvi2026-09-12T09:58:00-07:00Azacitidine và decitabine trong AML đột biến TP53: So sánh hiệu quả từ cơ sở dữ liệu COMMAND https://news.medxy.ai/comparative-effectiveness-of-azacitidine-and-decitabine-in-tp53-mutant-acute-myeloid-leukemia-insights-from-the-command-registry/Medxy AIen2026-09-12T09:57:39-07:00Comparative Effectiveness of Azacitidine and Decitabine in TP53-Mutant Acute Myeloid Leukemia: Insights from the COMMAND Registry https://news.medxy.ai/zh/multiple-myeloma-risk/Medxy AIzh2026-09-12T09:56:58-07:00新诊断多发性骨髓瘤风险分层再优化：循环肿瘤细胞识别 IMS-IMWG 2025 分期中的播散性基因组高危表型 https://news.medxy.ai/ja/multiple-myeloma-risk-2/Medxy AIja2026-09-12T09:56:40-07:00新規診断多発性骨髄腫のリスク層別化をさらに洗練する：循環腫瘍細胞が IMS-IMWG 2025 病期分類における播種性ゲノム高リスク表現型を同定 https://news.medxy.ai/vi/risk-stratification-myeloma/Medxy AIvi2026-09-12T09:56:20-07:00Tinh chỉnh phân tầng nguy cơ ở đa u tủy mới chẩn đoán: tế bào u tuần hoàn giúp nhận diện kiểu hình nguy cơ cao về bộ gen có tính lan tràn trong hệ thống phân giai đoạn IMS-IMWG 2025 https://news.medxy.ai/refining-risk-stratification-in-newly-diagnosed-multiple-myeloma-circulating-tumor-cells-identify-a-disseminated-genomic-high-risk-phenotype-within-ims-imwg-2025-staging/Medxy AIen2026-09-12T09:55:59-07:00Refining Risk Stratification in Newly Diagnosed Multiple Myeloma: Circulating Tumor Cells Identify a Disseminated Genomic High-Risk Phenotype Within IMS-IMWG 2025 Staging https://news.medxy.ai/zh/il-16-lymphoma-resistance/Medxy AIzh2026-09-12T09:55:12-07:00IL-16介导的B细胞淋巴瘤耐药机制：BTK抑制剂与R-CHOP失效的分子基础及治疗启示 https://news.medxy.ai/ja/btk-resistance-mechanism/Medxy AIja2026-09-12T09:54:53-07:00B細胞リンパ腫におけるBTK阻害薬・R-CHOP抵抗性の新たな機序：IL-16産生が担う役割と治療戦略 https://news.medxy.ai/vi/il-16-drug-resistance/Medxy AIvi2026-09-12T09:54:33-07:00IL-16 tạo ra cơ chế kháng thuốc với chất ức chế BTK và R-CHOP trong u lympho tế bào B: hiểu biết cơ chế và ý nghĩa điều trị https://news.medxy.ai/il-16-production-as-a-mechanism-of-resistance-to-btk-inhibitors-and-r-chop-in-b-cell-lymphomas-mechanistic-insights-and-therapeutic-implications/Medxy AIen2026-09-12T09:54:11-07:00IL-16 Production as a Mechanism of Resistance to BTK Inhibitors and R-CHOP in B-Cell Lymphomas: Mechanistic Insights and Therapeutic Implications https://news.medxy.ai/zh/arlocabtagene-autoleucel-multiple-myeloma/Medxy AIzh2026-09-12T09:53:17-07:00Arlocabtagene Autoleucel：为多线治疗后的复发/难治性多发性骨髓瘤带来新的治疗思路 https://news.medxy.ai/ja/arlocabtagene-multiple-myeloma/Medxy AIja2026-09-12T09:52:59-07:00重前治療例の再発・難治性多発性骨髄腫に挑むArlocabtagene Autoleucel：治療パラダイムを変える可能性 https://news.medxy.ai/vi/72790-2/Medxy AIvi2026-09-12T09:52:38-07:00Arlocabtagene Autoleucel: Một phương pháp điều trị mới cho đa u tủy xương tái phát/kháng trị sau nhiều đợt điều trị https://news.medxy.ai/arlocabtagene-autoleucel-advancing-treatment-paradigms-in-heavily-pretreated-relapsed-refractory-multiple-myeloma/Medxy AIen2026-09-12T09:52:18-07:00Arlocabtagene Autoleucel: Advancing Treatment Paradigms in Heavily Pretreated Relapsed/Refractory Multiple Myeloma https://news.medxy.ai/zh/chronic-critical-care-goals/Medxy AIzh2026-09-12T09:51:31-07:00慢性危重症中治疗目标的医师心智模型：对共享决策的启示 https://news.medxy.ai/ja/chronic-disease-treatment-goals/Medxy AIja2026-09-12T09:51:10-07:00慢性重症疾患における治療目標をめぐる医師のメンタルモデルを読み解く――共同意思決定への示唆 https://news.medxy.ai/vi/doctor-mental-models/Medxy AIvi2026-09-12T09:50:48-07:00Hiểu mô hình tinh thần của bác sĩ về mục tiêu chăm sóc trong bệnh nặng mạn tính: Hàm ý cho ra quyết định chung https://news.medxy.ai/physicians-goals-care/Medxy AIen2026-09-12T09:50:25-07:00Understanding Physicians’ Mental Models on Goals of Care in Chronic Critical Illness: Implications for Shared Decision Making https://news.medxy.ai/zh/tezepelumab-asthma-study-3/Medxy AIzh2026-09-12T09:49:43-07:00Tezepelumab 在多种重度哮喘表型中均展现出稳健的疗效与安全性：来自 4 期 PASSAGE 研究的启示 https://news.medxy.ai/ja/tezepelumab-asthma-effectiveness/Medxy AIja2026-09-12T09:49:23-07:00多様な重症喘息表現型におけるテゼペルマブの有効性・安全性を検証：第4相PASSAGE試験の知見 https://news.medxy.ai/vi/tezepelumab-efficacy-safety/Medxy AIvi2026-09-12T09:48:59-07:00Tezepelumab cho thấy hiệu quả và độ an toàn vượt trội trên nhiều kiểu hình hen nặng: Góc nhìn từ nghiên cứu PASSAGE pha 4 https://news.medxy.ai/tezepelumab-demonstrates-robust-efficacy-and-safety-across-diverse-severe-asthma-phenotypes-insights-from-the-phase-4-passage-study/Medxy AIen2026-09-12T09:48:38-07:00Tezepelumab Demonstrates Robust Efficacy and Safety Across Diverse Severe Asthma Phenotypes: Insights from the Phase 4 PASSAGE Study https://news.medxy.ai/zh/dupilumab-copd-benefits-2/Medxy AIzh2026-09-12T09:47:53-07:00Dupilumab 降低 COPD 急性加重、急诊就诊与糖皮质激素使用：来自 3 期合并分析的研究启示 https://news.medxy.ai/ja/72768-2/Medxy AIja2026-09-12T09:47:36-07:00デュピルマブはCOPDの増悪、救急外来受診、および糖質コルチコイド使用を減少させる https://news.medxy.ai/vi/dupilumab-copd-benefits/Medxy AIvi2026-09-12T09:47:17-07:00Dupilumab giúp giảm đợt cấp COPD, lượt khám cấp cứu và sử dụng corticosteroid: Kết quả từ phân tích gộp giai đoạn 3 https://news.medxy.ai/efficacy-of-dupilumab-in-reducing-copd-exacerbations-emergency-department-visits-and-corticosteroid-use-insights-from-a-pooled-phase-3-analysis/Medxy AIen2026-09-12T09:46:57-07:00Efficacy of Dupilumab in Reducing COPD Exacerbations, Emergency Department Visits, and Corticosteroid Use: Insights from a Pooled Phase 3 Analysis https://news.medxy.ai/zh/retinal-sensitivity-impacts/Medxy AIzh2026-09-12T09:46:11-07:00中间期年龄相关性黄斑变性中不同亚型网状假性玻璃膜疣对视网膜敏感度的差异影响 https://news.medxy.ai/ja/retinal-sensitivity-macular-degeneration/Medxy AIja2026-09-12T09:45:50-07:00中間期加齢黄斑変性における網状偽ドルーゼン亜型が網膜感度に及ぼす影響の違い https://news.medxy.ai/vi/reticular-pseudodrusen-effects/Medxy AIvi2026-09-12T09:45:28-07:00Phân nhóm reticular pseudodrusen ảnh hưởng khác nhau đến độ nhạy cảm võng mạc trong thoái hóa hoàng điểm liên quan tuổi giai đoạn trung gian https://news.medxy.ai/differential-impact-of-reticular-pseudodrusen-subtypes-on-retinal-sensitivity-in-intermediate-age-related-macular-degeneration/Medxy AIen2026-09-12T09:45:07-07:00Differential Impact of Reticular Pseudodrusen Subtypes on Retinal Sensitivity in Intermediate Age-Related Macular Degeneration https://news.medxy.ai/zh/dupilumab-atopic-dermatitis-eye/Medxy AIzh2026-09-12T09:44:23-07:00dupilumab治疗特应性皮炎相关眼表疾病：来自大型前瞻性 BioDay 队列的研究发现 https://news.medxy.ai/ja/dupilumab-eye-conditions/Medxy AIja2026-09-12T09:44:04-07:00アトピー性皮膚炎におけるdupilumab関連眼表面疾患を読み解く：BioDay大規模前向きコホートからの知見 https://news.medxy.ai/vi/dupilumab-eye-disease/Medxy AIvi2026-09-12T09:43:43-07:00Dupilumab và bệnh lý bề mặt nhãn cầu trong viêm da cơ địa: phát hiện từ đoàn hệ tiến cứu BioDay quy mô lớn https://news.medxy.ai/unveiling-dupilumab-associated-ocular-surface-disease-in-atopic-dermatitis-insights-from-a-large-prospective-bioday-cohort/Medxy AIen2026-09-12T09:43:24-07:00Unveiling Dupilumab-Associated Ocular Surface Disease in Atopic Dermatitis: Insights from a Large Prospective BioDay Cohort https://news.medxy.ai/zh/satralizumab-thyroid-eye-disease/Medxy AIzh2026-09-12T09:42:46-07:00Satralizumab 在甲状腺眼病治疗中展现出良好疗效与安全性：来自 SatraGO-1 和 SatraGO-2 Ⅲ期试验的启示 https://news.medxy.ai/ja/satralizumab-thyroid-eye-disease-2/Medxy AIja2026-09-12T09:42:26-07:00甲状腺眼症に対するsatralizumab、第3相試験で有望な有効性と安全性を示す https://news.medxy.ai/vi/satralizumab-eye-treatment/Medxy AIvi2026-09-12T09:42:03-07:00Satralizumab cho thấy hiệu quả và độ an toàn đầy hứa hẹn trong điều trị bệnh mắt tuyến giáp: Góc nhìn từ các thử nghiệm pha 3 SatraGO-1 và SatraGO-2 https://news.medxy.ai/satralizumab-demonstrates-promising-efficacy-and-safety-in-treating-thyroid-eye-disease-insights-from-phase-3-satrago-1-and-satrago-2-trials/Medxy AIen2026-09-12T09:41:42-07:00Satralizumab Demonstrates Promising Efficacy and Safety in Treating Thyroid Eye Disease: Insights from Phase 3 SatraGO-1 and SatraGO-2 Trials https://news.medxy.ai/ja/vocal-fatigue-vaping/Medxy AIja2026-09-12T09:40:52-07:00電子たばこ使用者における音声疲労の有病率と口腔乾燥症との関連 https://news.medxy.ai/vi/vocal-fatigue-vapers/Medxy AIvi2026-09-12T09:40:29-07:00Mệt mỏi giọng nói ở người hút thuốc lá điện tử và mối liên hệ với khô miệng https://news.medxy.ai/prevalence-of-voice-fatigue-and-its-correlation-with-xerostomia-in-e-cigarette-smokers/Medxy AIen2026-09-12T09:40:09-07:00Prevalence of Voice Fatigue and Its Correlation With Xerostomia in E-Cigarette Smokers https://news.medxy.ai/zh/child-nose-battery-removal/Medxy AIzh2026-09-12T09:39:07-07:00儿童鼻腔纽扣电池与磁铁取出后的长期结局及生活质量 https://news.medxy.ai/ja/long-term-outcome-pediatric-battery-removal/Medxy AIja2026-09-12T09:38:51-07:00小児の鼻腔内ボタン電池・磁石摘出後の長期転帰と生活の質 https://news.medxy.ai/vi/long-term-outcome-children/Medxy AIvi2026-09-12T09:38:31-07:00Kết cục lâu dài và chất lượng cuộc sống ở trẻ em sau khi lấy bỏ pin cúc áo và nam châm trong mũi https://news.medxy.ai/zh/cardiovascular-outcomes-cloning/Medxy AIzh2026-09-12T09:38:21-07:00克隆性造血中的心血管结局试验设计：精准医学的迫切任务 https://news.medxy.ai/long-term-outcomes-and-quality-of-life-in-children-following-nasal-button-battery-and-magnet-removal/Medxy AIen2026-09-12T09:38:13-07:00Long-Term Outcomes and Quality of Life in Children Following Nasal Button Battery and Magnet Removal https://news.medxy.ai/ja/cardiovascular-outcome-trial/Medxy AIja2026-09-12T09:38:04-07:00クローン性造血における心血管アウトカム試験の設計：精密医療に向けた必須課題 https://news.medxy.ai/vi/cardiovascular-trial-design/Medxy AIvi2026-09-12T09:37:42-07:00Thiết kế thử nghiệm kết cục tim mạch trong tạo huyết dòng vô định tiềm năng: Yêu cầu cấp thiết của y học chính xác https://news.medxy.ai/zh/us-robotic-vs-laparoscopic-cholecystectomy/Medxy AIzh2026-09-12T09:37:32-07:00美国机器人、腹腔镜与开腹胆囊切除术早期结局比较：全国性分析 https://news.medxy.ai/ja/robotic-laparoscopic-cholecystectomy/Medxy AIja2026-09-12T09:37:12-07:00米国におけるロボット・腹腔鏡・開腹胆嚢摘出術の早期成績を比較：全国解析 https://news.medxy.ai/vi/robotic-gallbladder-surgery/Medxy AIvi2026-09-12T09:36:45-07:00Đánh giá kết cục sớm của cắt túi mật hỗ trợ robot so với nội soi và phẫu thuật mở tại Hoa Kỳ: Phân tích trên toàn quốc https://news.medxy.ai/evaluating-early-outcomes-of-robotic-versus-laparoscopic-and-open-cholecystectomy-in-the-us-a-nationwide-analysis/Medxy AIen2026-09-12T09:36:24-07:00Evaluating Early Outcomes of Robotic versus Laparoscopic and Open Cholecystectomy in the US: A Nationwide Analysis https://news.medxy.ai/zh/ptsd-risk-prediction/Medxy AIzh2026-09-12T09:35:34-07:00枪伤幸存者 PTSD 风险预测：休克指数、低血压与输血的作用 https://news.medxy.ai/ja/ptsd-prediction-gunshot/Medxy AIja2026-09-12T09:35:17-07:00銃創生存者のPTSDを予測するには？ ショックインデックス・低血圧・輸血の役割 https://news.medxy.ai/vi/ptsd-prediction-survivors/Medxy AIvi2026-09-12T09:34:51-07:00Dự đoán PTSD ở người sống sót sau vết thương do súng bắn: Vai trò của chỉ số sốc, hạ huyết áp và truyền máu https://news.medxy.ai/predicting-ptsd-in-gunshot-wound-survivors-the-role-of-shock-index-hypotension-and-blood-transfusion/Medxy AIen2026-09-12T09:34:30-07:00Predicting PTSD in Gunshot Wound Survivors: The Role of Shock Index, Hypotension, and Blood Transfusion